Microbot Medical
MBOT
32 hedge funds and large institutions have $1.41M invested in Microbot Medical in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.
700% more call options, than puts
Call options by funds: $16K | Put options by funds: $2K
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
14% more funds holding
Funds holding: 28 → 32 (+4)
1.99% less ownership
Funds ownership: 10.56% → 8.57% (-2%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
58% less capital invested
Capital invested by funds: $3.36M → $1.41M (-$1.95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$112K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$85.6K |
| 3 |
Renaissance Technologies
New York
|
+$77.9K |
| 4 |
VF
Virtu Financial
New York
|
+$51.9K |
| 5 |
TFCM
Taylor Frigon Capital Management
Scottsdale,
Arizona
|
+$27.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.05M |
| 2 |
Millennium Management
New York
|
-$27.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$19.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.44K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$4K |
MBOT Hedge Fund Activity: Q3 2023 in Review
32 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Microbot Medical (MBOT) for Q3 2023, worth a combined $1.41M — down 58% from $3.36M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MBOT positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $112K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.05M sold.
- 32 institutional investors held Microbot Medical (MBOT) as of Q3 2023, up from 28 in Q2 2023.
- Funds reported $1.41M of Microbot Medical stock for Q3 2023, down 58% quarter-over-quarter.
- 7 funds opened new Microbot Medical positions in Q3 2023 and 3 closed out, a net change of +4 holders.
- The largest Microbot Medical buyer in Q3 2023 was Citadel Advisors, an estimated $112K added.
- The largest Microbot Medical seller in Q3 2023 was Armistice Capital, an estimated $1.05M sold.
Based on aggregated 13F filings for Q3 2023.